Several multigene molecular signatures, including the Oncotype DX 21-gene recurrence score, MammaPrint 70-gene signature, PAM50-based Prosigna risk of recurrence, and EndoPredict, have been developed to better predict recurrence or distant metastasis in patients with hormone receptor-positive early breast cancer [5, 6]. This evidence concerns the gene NR4A1 and breast carcinoma.